This company listing is no longer active
SBI Stock Overview
Sourcebio International Plc, together with its subsidiaries, provides various laboratory services and products to clients in the healthcare, clinical, life science research, and biopharma industries in the United Kingdom, Europe, the United States, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Sourcebio International Plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£1.15 |
52 Week High | UK£1.70 |
52 Week Low | UK£0.90 |
Beta | 0.024 |
1 Month Change | 2.22% |
3 Month Change | -8.00% |
1 Year Change | -32.35% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -32.75% |
Recent News & Updates
Shareholder Returns
SBI | GB Healthcare | GB Market | |
---|---|---|---|
7D | 9.5% | 0.5% | 2.2% |
1Y | -32.4% | -21.8% | 3.7% |
Return vs Industry: SBI underperformed the UK Healthcare industry which returned 3.2% over the past year.
Return vs Market: SBI underperformed the UK Market which returned -7.7% over the past year.
Price Volatility
SBI volatility | |
---|---|
SBI Average Weekly Movement | 5.2% |
Healthcare Industry Average Movement | 7.6% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SBI has not had significant price volatility in the past 3 months.
Volatility Over Time: SBI's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 339 | n/a | https://sourcebiointernational.com |
Sourcebio International Plc, together with its subsidiaries, provides various laboratory services and products to clients in the healthcare, clinical, life science research, and biopharma industries in the United Kingdom, Europe, the United States, and internationally. The company’s services cover histopathology cancer screening and clinical diagnostic services; DNA sequencing services and precision medicine to pharmaceutical and biotechnology companies, academia, contract research organizations, and other research markets; shelf-life testing services and equipment; and COVID-19 antigen PCR testing services. It also manufactures library clones, direct to consumer home test kits, and blood and tissue serological products; and provides employee testing solutions and venue testing.
Sourcebio International Plc Fundamentals Summary
SBI fundamental statistics | |
---|---|
Market cap | UK£85.31m |
Earnings (TTM) | UK£6.69m |
Revenue (TTM) | UK£75.61m |
12.7x
P/E Ratio1.1x
P/S RatioIs SBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SBI income statement (TTM) | |
---|---|
Revenue | UK£75.61m |
Cost of Revenue | UK£48.44m |
Gross Profit | UK£27.18m |
Other Expenses | UK£20.48m |
Earnings | UK£6.69m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 0.09 |
Gross Margin | 35.94% |
Net Profit Margin | 8.85% |
Debt/Equity Ratio | 0% |
How did SBI perform over the long term?
See historical performance and comparison